Evidence map›Paper›PMID 40709526›Full record

ReviewAlzheimer's & dementia : the journal of the Alzheimer's Association2025

Unveiling blood biomarkers for neuronal hyperplasticity: Insights from AD molecular subtyping, a comprehensive review.

Niti Sharma, Danyeong Kim, Himadri Sharma, Moon Il Kim, Hyon Lee, Minju Kim, Nayoung Ryoo, Min Ju Kang, Jung-Min Pyun, Young Ho Park and 15 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Niti SharmaDepartment of Bionano Technology, Gachon Bionano Research Institute, Gachon University, Seongnam, Republic of Korea.ORCID 0000-0001-6720-257X
Danyeong KimDepartment of Bionano Technology, Gachon Bionano Research Institute, Gachon University, Seongnam, Republic of Korea.
Himadri SharmaDepartment of Bionano Technology, Gachon Bionano Research Institute, Gachon University, Seongnam, Republic of Korea.
Moon Il KimDepartment of Bionano Technology, Gachon Bionano Research Institute, Gachon University, Seongnam, Republic of Korea.
Hyon LeeDepartment of Neurology, Gachon University Gil Hospital, Incheon, Republic of Korea.
Minju KimDepartment of Neurology, Seoul National University College of Medicine & Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
Nayoung RyooDepartment of Neurology, Eunpyeong St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea.
Min Ju KangDepartment of Neurology, Veterans Medical Research Institute, Veterans Health Service Medical Center, Seoul, Republic of Korea.
Jung-Min PyunDepartment of Neurology, Seoul National University College of Medicine & Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
Young Ho ParkDepartment of Research and Development, PeopleBio Inc, Seongnam, Republic of Korea.
Jisun RyuDepartment of Research and Development, PeopleBio Inc, Seongnam, Republic of Korea.
Hyun Jung OhDepartment of Research and Development, PeopleBio Inc, Seongnam, Republic of Korea.
Hyun-Sik YangDepartment of Neurology, Brigham and Women's Hospital/Harvard Medical School, Boston, USA.
Hang-Rai KimDepartment of Neurology, Dongguk University Ilsan Hospital, Goyang, Republic of Korea.
Geon Ha KimDepartment of Neurology, Ewha Woman's University Mokdong Hospital, Ewha Woman's University College of Medicine, Seoul, Republic of Korea.
Sangwon HanDepartment of Neurology, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Republic of Korea.
YoungSoon YangDepartment of Neurology, Soonchunhyang University Hospital, Cheonan, Republic of Korea.
Young Chul YounDepartment of Neurology, College of Medicine, Chung-Ang University, Seoul, Republic of Korea.
Charlotte TeunissenNeurochemistry Laboratory, Department of Clinical Chemistry, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
Henrik ZetterbergClinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
Philip ScheltensDepartment of Neurology & Alzheimer Center, Amsterdam University Medical Center, Amsterdam, Netherlands.
Seong Soo A AnDepartment of Bionano Technology, Gachon Bionano Research Institute, Gachon University, Seongnam, Republic of Korea.ORCID 0000-0002-8123-6183
Young-Bum KimDivision of Endocrinology, Diabetes, and Metabolism, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, USA.
SangYun KimDepartment of Neurology, Seoul National University College of Medicine & Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
Alzheimer's Disease All Markers (ADAM) Research Group

Funding

Korea Institute of Marine Science & Technology Promotion (KIMST) RS-2025-02292973Ministry of Education 2021R1A6A1A03038996Ministry of Education RS-2021-NR060117National Research Foundation of Korea RS-2023-00251396
6 · The paper itself

Abstract

Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder, predominantly affecting the aging population. Early detection through biomarkers is essential for early intervention. Recent sub-classification of AD through extensive cerebrospinal fluid (CSF) proteomic analyses revealed distinct characteristics of each subtype, necessitating tailored therapeutic strategies. While CSF proteomics has identified potential biomarkers, the need for non-invasive and cost-effective substitutions highlights the importance of blood-based biomarkers (BBMs). This review is a comprehensive review that categorizes potential BBMs based on neuronal hyperplasticity (subtype 1), underlining their role in refining subtype classification and enabling precision medicine. Early AD is often marked by cortical and hippocampal hyperactivity, followed by hypoactivity during later stages of neurodegeneration. While the exact mechanisms remain unclear, factors like Ca

Indexed as

Alzheimer DiseaseBiomarkersNeuronsHumansBiomarkersAlzheimer's diseaseblood biomarkersneuronal hyperplasticitypersonalized treatment

Identifiers

PMID40709526
PMCPMC12290491

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.